ArticlePloS one2025
The neuronal chaperone proSAAS is highly expressed in the retina.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The many layers of the neuroretina contain a complex, interconnected network of specialized neurons that both process visual stimuli and conduct processed information to higher brain areas. Neural networks rely on proteostatic control mechanisms to maintain proper protein homeostasis both in cell bodies as well as within synapses; protein chaperones play an important role in regulating and supporting this process. ProSAAS is a small neuronal chaperone that functions as an anti-aggregant in in vitro assays and is released upon depolarization in neuronal primary cultures. We here report a potential role for proSAAS in the retina. A review of human and mouse retinal RNAseq studies reveals that proSAAS expression is abundant within the retina. Single cell sequencing data from mouse and human studies show that proSAAS levels are highest in retinal ganglion cells (RGCs) and horizontal cells. Using proSAAS antibodies in combination with antisera to known retinal cell markers in mouse retinal sections, we confirm RNAseq data showing that proSAAS expression is highest in RGCs and horizontal cells. The proSAAS signal is concentrated within the ganglion cell layer and the inner plexiform layer, a dense synaptic layer connecting retinal neurons. Western blotting of mouse retinal extracts indicates the presence of two processed proSAAS forms, a 21 kDa C-terminally processed form, and a small 13 kDa species which, based on antibody specificity, likely represents an internal fragment. This fragment is also found in extracts prepared from human retinas. Taken together, our data provide support for the hypothesis that retinal synapses utilize the proSAAS chaperone to support visual signaling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.